Purpose The Alzheimer's disease (AD) pathology is characterized by fibrillar amyloid deposits and neurofibrillary tangles, as well as the activation of astrocytosis, microglia activation, atrophy, dysfunctional synapse, and cognitive impairments. The aim of this study was to test the hypothesis that astrocytosis is correlated with reduced gray matter density in prodromal AD. Methods Twenty patients with AD or mild cognitive impairment (MCI) underwent multi-tracer positron emission tomography (PET) studies with C-deuterium-L-deprenyl ( 11 C-DED) PET imaging, as well as magnetic resonance imaging (MRI) scanning, cerebrospinal fluid (CSF) biomarker analysis, and neuropsychological assessments. The parahippocampus was selected as a region of interest, and each value was calculated for four different imaging modalities. Correlation analysis was applied between DED slope values and gray matter (GM) densities by MRI. To further explore possible relationships, correlation analyses were performed between the different variables, including the CSF biomarker. Results A significant negative correlation was obtained between DED slope values and GM density in the parahippocampus in PIB-positive (PIB+ve) MCI patients (p=0.025) (prodromal AD). Furthermore, in exploratory analyses, a positive correlation was observed between PIB-PET retention and DED binding in AD patients (p=0.014), and a negative correlation was observed between PIB retention and CSF Aβ42 levels in MCI patients (p=0.021), while the GM density and CSF total tau levels were negatively correlated in both PIB + ve MCI (p=0.002) and MCI patients (p=0.001). No significant correlation was observed with FDG-PET and with any of the other PET, MRI, or CSF biomarkers. Conclusions High astrocytosis levels in the parahippocampus of PIB+ve MCI (prodromal AD) patients suggest an early preclinical influence on cellular tissue loss. The lack of correlation between astrocytosis and CSF tau levels, and a positive correlation between astrocytosis and fibrillar amyloid deposition in clinical demented AD together indicate that parahippocampal astrocytosis might have some causality within the amyloid pathology.
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Introduction
The classical hallmarks of Alzheimer's disease (AD) pathology are the presence of amyloid plaques and neurofibrillary tangles, but other processes such as inflammation (astrocytosis, microgliosis) are also believed to be possible pathophysiologic events of AD [1] .
The brain astrocyte, which is reactive in the brain against infection and injury, has been proposed to exert an important role in AD when activated through neuroinflammation [2] . The enzyme monoamine oxidase B (MAO-B) exists on the outer mitochondrial membrane, predominantly in astrocytes [3] [4] [5] . L-deprenyl is an irreversible MAO-B inhibitor, and the positron emission tomography (PET) tracer 11 C-deuterium-Ldeprenyl ( 11 C-DED) has a high affinity and specificity for MAO-B [6] . Three studies have been published using 11 C-DED PET in AD patients [7] [8] [9] , and one of these studies demonstrated an increased 11 C-DED binding especially in patients with mild cognitive impairment (MCI), suggesting that inflammation is an early phenomenon of AD pathology [7] .
New biomarker-based diagnostic criteria have been proposed to enhance the clinical detection of AD in early prodromal stages of the disease. Biomarkers recommended by these criteria include amyloid tracer uptake and 1 8 Ffluorodeoxyglucose ( 18 F-FDG) using PET, medial temporal lobe atrophy as assessed by structural MRI, and cerebrospinal fluid (CSF) biomarkers including Aβ1-42, total tau (tTau), and phosphorylated tau (pTau) [10] [11] [12] .
In addition to these biomarkers, 11 C-DED PET imaging of astrocytosis (neuroinflammation) may help to further understand the AD pathophysiology. Several previous studies have tried to explore relationships between the suggested biomarkers; most of them used a combination of two or three biomarkers [13] [14] [15] [16] [17] [18] [19] [20] . In one CSF study a relationship was reported between cerebral brain volumes and CSF tau in AD patients and Aβ42 in cognitively normal subjects, respectively [18] . Several studies have evaluated correlations between amyloid accumulation and cerebral glucose metabolism in AD, MCI, or cognitively normal elderly patients [15-17, 19, 20] , while others examined the relationships between amyloid and cerebral volume in cognitively normal patients and those with subjective cognitive impairment, mild cognitive impairment, or AD [13, 14] .
In this study, we hypothesized that in the parahippocampus, which is known as a region showing early destructive tau pathology processes [21] and structural changes [22] during AD progression, neuronal astrocytosis is correlated with reduced gray matter density in prodromal AD. To test this hypothesis, we examined the relationship between astrocytosis and gray matter density using 11 C-DED with MRI in MCI and AD patients. In addition, we also explored possible relationships between amyloid plaque load, regional glucose metabolism, astrocytosis, and gray matter density using 11 C-PIB/ 11 C-DED/ 18 F-FDG PET with MRI and CSF biomarkers.
Materials and methods

Subjects
Twenty patients (13 MCI and seven AD patients) were recruited from the Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden. The patients had undergone clinical memory assessment after being referred from primary care centers in the community for investigation of suspected cognitive disorders. The patients underwent comprehensive clinical examination, electroencephalogram, MRI, and CSF and blood analysis including APOE genotyping, and neuropsychological testing. The diagnosis of MCI followed the clinical criteria as defined by Petersen et al. [23] : memory complaint, objective memory impairment (1.5 standard deviations (SD) below agematched controls) [24] , normal general cognitive function, intact daily living, and not fulfilling the DSM-IV criteria for dementia (American Psychiatric Association, 1994). AD met the clinical criteria of the DSM-IV criteria for dementia and the National Institute of Neurological and Communication Disorders, Alzheimer's Disease and Related Disorders Association (NINCSD-ADRDA) criteria for AD [25] . All patients underwent multi-tracer PET studies with C-DED/ 18 F-FDG PET images were co-registered and re-sliced to their individual T1 reference image. All T1 reference images were segmented into gray matter (GM) and white matter tissue classes using the unified segmentation algorithm of SPM8. The resultant probabilistic GM density map for each participant had a threshold of 0.5 applied to it, and a binary GM mask was created (0, no tissue, and 1, tissue with a>50 % probability belonging to GM). The inverse nonlinear transformation parameter file from SPM's segmentation algorithm was used to warp a simplified digital probabilistic atlas [26] , consisting of 26 cortical and subcortical regions, into each individual's native T1 space. These atlases were multiplied by the corresponding binary GM mask, which generated a GM-specific digital atlas for each participant. Raw, co-registered, and re-sliced PET and MRI data for each patient were sampled using the same individual digital atlases created previously. Mean PET uptake and MRI gray matter density were measured for each atlas region using this method. Regional metabolic rates of glucose were created for 18 F-FDG PET and each atlas region by dividing by the respective mean pontine glucose metabolic rate. For 
Cerebrospinal fluid biomarker measurements
Cerebrospinal fluid (CSF) was obtained by lumbar puncture performed in non-fasting subjects between 8-11 a.m. at the Memory Clinic, Karolinska University Hospital. CSF samples with more than 500 erythrocytes/μl were excluded. All samples were centrifuged for 10 minutes at 3,000 xg and 4ºC immediately after collection. The supernatant was aliquoted after careful mixing to avoid gradient effects, and samples were stored at −80ºC until analysis. Measurement of total tau (tTau), phosphorylated tau (pTau), and amyloid-β1-42 (Aβ1-42) in CSF was performed using a sandwich enzyme-linked immunosorbent assays (ELISA) (INNO-BIA AlzBio3 assay, Innogenetics, Ghent, Belgium) [27] [28] [29] .
Neuropsychological assessments
An experienced neuropsychologist performed cognitive assessments. These neuropsychological tests assess specific domains such as verbal abilities (Similarities and Information), visuospatial abilities (Block Design and Rey-Osterrieth copy), episodic memory (Rey Auditory Verbal Learning and Retention after 30 min; Rey-Osterrieth Retention after 30 min), and attention and executive function (Trail-making Test A and B). Detailed information regarding the above-mentioned tests has been described previously [30] . All cognitive raw scores were z-transformed using reference data from healthy adults at the Geriatric Clinic, Karolinska University Hospital, Huddinge [31] .
Statistical analysis
The MCI subjects were categorized according to 11 C-PIB retention data into PIB-negative (PIB-ve) and PIBpositive (PIB+ve) groups, which were defined with a neocortical retention ratio cut-off value of 1.41, as described in our earlier European multicenter study on 11 C-PIB [32] . To explore multimodal correlations in the AD continuum, subjects were divided into three groups: PIB-ve MCI; PIB+ve MCI; and those who were diagnosed as AD (AD). To compare characteristics of the defined three groups, we applied analysis of variance (ANOVA) tests for age, education, and Mini Mental State Examination (MMSE), chi-squared tests for gender and APOE ε4 allele numbers, and KruskalWallis tests for values of the four imaging modalities and CSF biomarkers of Aβ1-42, tTau, and pTau. For the region of interest (ROI) of the parahippocampus, mean values of the DED binding slope, PIB retention ratio, glucose metabolic rate, and GM density were acquired from the four different imaging modalities of 11 C-DED/ 11 C-PIB/ 18 F-FDG PET, and MRI. Spearman's correlation analyses were performed using SPSS version 18. To test our hypothesis, statistical significance was defined as p<0.05 for correlation between DED binding slope values and GM density in the parahippocampus. With the aim of exploration, we carried out additional correlation analyses between DED binding slope values and PIB retention ratio, glucose metabolic rate, and CSF biomarkers of Aβ1-42 and tTau, applying a significance level of p < 0.05 without correction of multiple comparisons.
Results
Characteristics of PIB-ve MCI, PIB+ve MCI, and AD patients
The demography and clinical data of patients are summarized in Table 1 . No significant difference was observed in age, gender, education, APOE ε4 allele numbers, and MMSE score between the groups. The PIB-ve MCI and PIB+ve MCI groups demonstrated comparable mean MMSE score values, whereas the MMSE score was lower for the AD group but did not reach statistical significance. Group differences were observed for mean parahippocampal gray matter density/ PIB retention ratio and CSF Aβ1-42 (Kruskal-Wallis; p < 0.05). There was no significant difference in mean parahippocampal DED slope values/glucose metabolic rate, and CSF tTau/pTau between the three groups. Neuropsychological test results among the groups are presented in Supplementary Table 1 .
Correlation between 11 C-Deprenyl binding slope values and gray matter density in the parahippocampus A significant negative correlation between DED binding slope values and GM density was found only in the PIB+ve MCI group (p=−0.733, p=0.025) ( Table 2 , Fig. 1 ), while significant correlation was not observed in the other patient groups. MCIMild cognitive impairment subjects; ADAlzheimer's disease patients; DED11C-deuterium-L-deprenyl; PIB11C-Pittsburg Compound-B; PIB-ve PIB-negative, which has a low PIB retention ratio; PIB+vePIB-positive, which has a high PIB retention ratio; APOE ε4number of subjects carrying at least one apolipoprotein ε4 allele; tTautotal tau; pTauphosphorylated tau; Aβ1-42amyloid β1-42; values are mean (SD) except number/sex/APOE ε4 MCIMild cognitive impairment subjects; ADAlzheimer's disease patients; PIB11C-Pittsburg Compound-B retention ratio; PIB-vePIB-negative, which has a low PIB retention ratio; PIB+vePIB-positive, which has a high PIB retention ratio; DED11C-Deprenyl regional binding slope; MRIRegional gray matter density; Exploratory correlations between CSF biomarkers and four different imaging modalities in the parahippocampus Table 3 and Supplementary Figure 2 summarize the correlation for CSF and imaging biomarkers. A significant negative correlation was observed between MRI gray matter density and CSF total tau levels in PIB+ve MCI (ρ=−0.883, p= 0.002) patients. The AD patients showed a significant negative correlation between PIB retention and CSF total tau levels (ρ=−0.893, p=0.007).
Discussion
The rapid development of PET molecular imaging techniques provides important possibilities to understand the time course of complex pathophysiological processes in AD. In the present study, levels of amyloid plaque deposition, astrocytosis, and cerebral glucose metabolism were compared to gray matter density measured by MRI. The hippocampus is wellknown from pathological studies to be characterized by high levels of astrocytosis and tau phosphorylation, while the amyloid plaque load is low, and is instead much higher in cortical brain regions of AD brains. In a recent study, we performed invitro autoradiography studies using [ 3 H]-deprenyl demonstrated high binding to activated astrocytes throughout the hippocampus [33] . The present study demonstrates in vivo that parahippocampal astrocytosis assessed by 11 C-DED PET is correlated with reduced GM density measured by MRI in PIBpositive MCI patients (prodromal AD). Moreover, we also MCIMild cognitive impairment subjects; ADAlzheimer's disease patients; PIB11C-Pittsburg Compound-B retention ratio; PIB-vePIB-negative, which has a low PIB retention ratio; PIB+vePIB-positive, which has a high PIB retention ratio; DED11C-Deprenyl regional binding slope; MRIRegional gray matter density; FDGRegional 18 F-Fluorodeoxyglucose metabolism; CSFCerebrospinal fluid biomarkers such as total tau (tTau) or amyloid β1-42 (Aβ1-42)
found that clinically demented AD patients showed a positive correlation between astrocytosis and PIB accumulation by 11 C-PIB PET in the parahippocampus. The significant negative correlation between astrocytosis and GM density in PIB+ve MCI patients may suggest that parahippocampal inflammation may influence and/or be influenced by gray matter cell loss in prodromal AD patients, while less active astrocytosis exists in clinically demented AD patients [7] . The positive correlation we observed in the parahippocampus between 11 C-DED binding and 11 C-PIB retention is most probably due to the fact that despite low 11 C-PIB retention in the hippocampus of AD patients, there is an increasing deposition of amyloid plaques in the hippocampus in clinical AD compared to MCI as measured by 11 C-PIB [32] .
We observed a significant negative correlation between the GM density of the parahippocampus and CSF tTau levels in PIB+ve MCI patients. This finding is consistent with previous studies reporting that neurofibrillary tangles are responsible for cerebral atrophy, especially in the medial temporal lobe [34] [35] [36] . Interestingly, we observed no relationship between astrocytosis ( 11 C-DED binding) and CSF tTau levels, suggesting that astrocytosis in the parahippocampus of clinically demented AD patients is related to amyloid pathology rather than tau, which is in line with previous studies suggesting that dysregulation of Aβ clearance by astrocytes may be responsible for its accumulation in AD [37] [38] [39] .
Taken together, our findings suggest that astrocytosis in the parahippocampus of prodromal AD patients might influence gray matter cell loss, but in clinically demented AD patients, astrocytosis is less related to cerebral cell loss, and more to amyloid processes.
In our current analysis, we did not observe any significant relationships between cerebral glucose metabolism in the parahippocampus and other measured parameters. Impairment in cerebral glucose metabolism has generally been described as a later phenomenon in the time course of AD in comparison to astrocytosis, amyloid brain deposition, and changes in CSF biomarkers [40, 41] . A negative correlation between amyloid plaque deposition and a decline in cerebral glucose metabolism has been reported in the temporal or parietal cortex for AD and MCI patients [15] [16] [17] 19] . Recently, a significant negative relationship between atrophy and cerebral glucose metabolism was demonstrated in the hippocampus and precuneus of AD patients [20] . A significant correlation between amyloid plaque load and atrophy measured by PET has solely been demonstrated in the temporoparietal cortex of subjects with subjective cognitive impairment [14] . As far as we know, to date, no studies have demonstrated any significant correlations between the three imaging modalities in the parahippocampus.
To our knowledge, the present study is the first to explore a multimodal biomarker profile in the parahippocampus at different stages of AD. Our study suggests that during AD pathology processes, astrocytosis may influence neuronal cell structure and tissue loss, especially in prodromal AD, when the amyloid pathology is less prominent as it is in more advanced clinical AD. Thus, PET imaging of astrocytosis has the potential to be a tool for early detection and use in prevention trials of disease-modifying therapies.
